These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31521657)

  • 1. Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2.
    Fayyazi N; Fassihi A; Esmaeili S; Taheri S; Ghasemi JB; Saghaie L
    Int J Biol Macromol; 2020 Jan; 142():94-113. PubMed ID: 31521657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. '
    H Ibraheim M; Maher I; Khater I
    J Biomol Struct Dyn; 2024 Nov; 42(18):9571-9586. PubMed ID: 37753739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
    Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
    Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors.
    Mahmoud MA; Mohammed AF; Salem OIA; Almutairi TM; Bräse S; Youssif BGM
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305856. PubMed ID: 38326989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
    Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
    Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A series of quinazolin-4(3H)-one-morpholine hybrids as anti-lung-cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies.
    Tokalı FS; Şenol H; Ateşoğlu Ş; Akbaş F
    Chem Biol Drug Des; 2024 Jul; 104(1):e14599. PubMed ID: 39039616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
    Brave SR; Odedra R; James NH; Smith NR; Marshall GB; Acheson KL; Baker D; Howard Z; Jackson L; Ratcliffe K; Wainwright A; Lovick SC; Hickinson DM; Wilkinson RW; Barry ST; Speake G; Ryan AJ
    Int J Oncol; 2011 Jul; 39(1):271-8. PubMed ID: 21537841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents.
    Pathak A; Pandey V; Raj Pokharel Y; Devaraji V; Ali A; Haider K; Saad S; Dewangan RP; Siddiqui N; Shahar Yar M
    Bioorg Chem; 2021 Nov; 116():105358. PubMed ID: 34544029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
    Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
    Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
    Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
    Molecules; 2021 May; 26(10):. PubMed ID: 34069962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
    Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
    Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.